IntrinsicIntrinsic
← All summaries

EXACT SCIENCES CORP

EXAS
Financials & Chart →

Business Summary

Exact Sciences Corporation operates as a leading provider of cancer screening and diagnostic tests, aiming to offer clarity for earlier, life-changing action. The company's core business model revolves around generating revenue from laboratory testing services, primarily through its Cologuard and Oncotype DX tests, and is actively investing in a pipeline of innovative solutions for various stages of cancer diagnosis . The company's primary customer is the patient, but it does not enter into formal reimbursement contracts with patients, instead relying on established billing rates less contractual and other adjustments, historical collections, and payer reimbursement contracts to determine revenue .

Exact Sciences' product and service portfolio is divided into Screening and Precision Oncology tests. The Screening segment includes the Cologuard and Cologuard Plus tests, which are non-invasive, stool-based DNA screening tests for colorectal cancer and pre-cancer, indicated for average-risk adults aged 45 and older . The Cologuard Plus test, launched in March 2025, demonstrated 95% cancer sensitivity, 94% Stage I-III cancer sensitivity, 74% high-grade dysplasia sensitivity, and 91% specificity in its BLUE-C clinical trial . The company estimates a potential $22 billion annual market for its Cologuard tests, based on nearly 110 million Americans aged 45-85 at average risk for colorectal cancer, a three-year screening interval, and an average revenue per test of approximately $592 for Cologuard Plus . Also in the Screening segment is the Cancerguard test, launched in September 2025 as a self-pay laboratory developed test (LDT), designed to detect multiple cancers from a single blood draw, showing 68% sensitivity across six deadly cancers and 64% overall sensitivity across a broad range of cancers (excluding breast and prostate), with 97.4% specificity in the ASCEND-2 study . Genetic testing, including predefined genetic tests, custom panels, and comprehensive germline, whole exome (PGxome), and whole genome (PGnome) sequencing tests, is also part of the Screening portfolio .

The Precision Oncology segment offers tests that provide genomic insights for prognosis and cancer treatment. Key products include the Oncotype DX Breast Recurrence Score test, which identifies patients likely to benefit from chemotherapy and is recognized globally as a standard of care . The Oncotype DX Breast DCIS Score test provides individualized 10-year risk prediction of local recurrence for DCIS patients . The Oncotype DX Colon Recurrence Score test predicts recurrence risk in stage II and stage III A/B colon cancer patients . The tumor-informed Oncodetect MRD test, launched as an LDT in April 2025, detects small amounts of tumor DNA post-treatment, achieving 78% sensitivity at the post-surgical timepoint and 91% sensitivity during surveillance monitoring, with specificities of 80% and 94% respectively, in the Alpha-CORRECT study . The OncoExTra test, acquired in April 2021, applies comprehensive tumor profiling for therapy selection in advanced cancers, covering approximately 20,000 genes and 169 introns . Finally, the Riskguard hereditary cancer test helps individuals understand their inherited cancer risk .

For the fiscal year ended December 31, 2025, Exact Sciences reported total revenue of $3,246,990 thousand , an 18% increase from the prior year . Gross profit was $2,262,755 thousand , resulting in a gross margin of 69.7% . Operating expenses totaled $2,469,053 thousand , leading to a loss from operations of $(206,298) thousand . Net loss for the year was $(207,949) thousand , and diluted EPS was $(1.10) . The company generated $491,438 thousand in net cash from operating activities . As of December 31, 2025, cash and cash equivalents stood at $955,996 thousand , and marketable securities were $8,715 thousand . Total indebtedness, consisting of convertible senior notes, was $2.35 billion .

Year-over-year, total revenue grew by $488,123 thousand, or 17.7% . Screening revenue increased by $425,998 thousand, or 20.2%, primarily due to higher Cologuard test volumes from increased rescreen rates, care gap programs, and new ordering providers . Precision Oncology revenue rose by $62,125 thousand, or 9.5%, driven by an increase in completed Oncotype DX breast cancer tests, particularly internationally in Japan . Gross margin remained consistent at 69.7% in 2025 compared to 69.5% in 2024, attributed to efficiencies in personnel and lab automation from increased Cologuard volume, partially offset by growth in care gap programs . Research and development expenses increased by $91,786 thousand, or 21.3%, primarily due to a $75.0 million upfront payment for a license deal with Freenome and increased resources for pipeline tests . Selling and marketing expenses grew by $156,058 thousand, or 17.5%, due to direct-to-consumer advertising and large screening programs . General and administrative expenses increased by $106,849 thousand, or 13.7%, mainly due to restructuring costs and incentive-based compensation, but decreased as a percentage of revenue due to efficiencies .

During 2025, Exact Sciences achieved several significant operational milestones. The company delivered over 5.5 million results to patients and launched Cologuard Plus, Oncodetect, and Cancerguard tests . Medicare reimbursement was obtained for the Oncodetect test, effective April 2025, for serial use in stage II, III, and resectable stage IV colorectal cancer patients over a five-year period . An exclusive license agreement was entered into with Freenome Holdings, Inc. for blood-based colorectal cancer screening . The company also announced a multi-year productivity plan in August 2025, targeting over $150 million in annual savings by 2026 through general and administrative efficiencies, restructuring support functions, and automation . In November 2025, Exact Sciences entered into a Merger Agreement with Abbott Laboratories, under which Abbott will acquire Exact Sciences for $105.00 per share in cash .

Business Outlook

Exact Sciences expects continued revenue growth for its Cologuard and Oncotype tests, subject to seasonal variability, timing of care gap programs, and additional growth from recent and upcoming product launches . The company anticipates that cash, cash equivalents, and marketable securities on hand at December 31, 2025, combined with cash flows from operations, will be sufficient to fund current operations through the expected closing date of the Merger, or for at least the next twelve months if the Merger is not completed or is delayed .

A major growth area for Exact Sciences is the expansion of its colorectal cancer screening tests. The company estimates that up to 55 million Americans are not up-to-date with colon cancer screenings, representing a significant opportunity . The company plans to partner with health systems and payers to implement Cologuard and Cologuard Plus tests within large, organized screening programs, including care gap programs, to address screening rates . The U.S. Supreme Court's affirmation in June 2025 of the ACA Mandate, requiring certain health insurers to cover USPSTF 'A' or 'B' rated preventive services without patient cost-sharing, reinforces the value of Cologuard and Cologuard Plus as valuable assets for payers . Furthermore, in August 2025, Exact Sciences acquired exclusive U.S. rights to current and future versions of Freenome's blood-based colorectal cancer screening tests and underlying technology, subject to regulatory approvals . Freenome submitted the final module of its premarket approval application to the FDA for the first-version test in mid-2025 .

Another significant growth vector is the development and commercialization of multi-cancer early detection (MCED) and molecular residual disease (MRD) tests. The Cancerguard test, an MCED blood test, was launched in September 2025 as a self-pay LDT . The company is actively enrolling patients for a real-world evidence study under a U.S. FDA-reviewed Investigational Device Exemption, designed to test 25,000 people over the next three years, to inform future regulatory submissions and support payer discussions . In the future, Exact Sciences plans to recruit patients for the FDA registrational Study of All comeRs (SOAR) trial, expected to be one of the largest prospective, interventional multi-cancer screening trials in the U.S. . For MRD, the Oncodetect test was launched in April 2025 as an LDT and obtained Medicare reimbursement effective April 2025 for serial use in stage II, III, and resectable stage IV colorectal cancer patients over a five-year period . The company plans to validate Oncodetect in breast cancer and other solid tumor types and expects to introduce a next-generation version in 2026 leveraging Broad Institute's MAESTRO technology, to which it secured exclusive rights in June 2023 .

Operationally, Exact Sciences expects cost of sales to generally increase in future periods due to increased laboratory testing services and pipeline product launches, with a corresponding increase in personnel and support services . However, the company anticipates sales and marketing expenses will decrease as a percentage of revenue over time, driven by the growth of Cologuard and Oncotype testing services . General and administrative expenses are expected to stabilize and decrease over time as the company leverages efficiencies in personnel, information technology systems, and benefits from its multi-year productivity plan . This multi-year productivity plan, announced in August 2025, aims to deliver over $150 million in expected annual savings by 2026, primarily from general and administrative efficiencies through external spend optimization, restructuring support functions, and automation .

Regarding capital allocation, Exact Sciences expects research and development expenditures to remain a significant portion of operating expenditures as it enhances current products and invests in its pipeline . The company plans to continue investing in capital expenditures to support the growth of existing products and R&D activities, with current projects including lab automation at its Madison, WI facilities, expected to be completed in 2026 and beyond . As of December 31, 2025, the company had $2.35 billion in outstanding convertible notes and access to a $500.0 million senior secured revolving credit agreement, with $494.1 million available for cash advances after accounting for issued letters of credit .

The company explicitly flags several structural headwinds and execution risks to its growth plan. These include the inherent uncertainties and complexities of developing and commercializing new tests, the need to secure and maintain adequate reimbursement rates from various payers, and intense competition from other companies . The success of new product launches, such as Cologuard Plus, Oncodetect, and Cancerguard, depends on market acceptance, inclusion in healthcare guidelines, and effective marketing . The company also highlights the risk that its estimates of total addressable markets for current and future products may be smaller than anticipated .

Geographic, regulatory, and macro factors identified as constraints include the complexities of international expansion, such as complying with multiple, conflicting, and changing laws, significant competition from local offerings, and difficulties in managing distributor relationships and reimbursement regimes . The EU IVDR, for example, imposes stricter requirements for in vitro diagnostics, requiring significant effort and expense for compliance . Macroeconomic conditions such as inflation, high interest rates, and foreign currency exchange rate fluctuations could adversely affect the business, impacting profitability and the ability of suppliers and partners to remain effective . The company also notes the substantial uncertainty regarding the future regulation of LDTs, which could lead to increased costs, delays, or decreased demand for its tests .

Risk Factors

Exact Sciences faces material risks including the potential failure or delay of the proposed Merger with Abbott Laboratories, which could result in a termination fee of approximately $628.7 million and adverse impacts on its stock price, business relationships, and financial condition. The company has incurred losses since inception, with a net loss of $207.9 million for the year ended December 31, 2025 , and may require additional capital to fund its strategic plan, which may not be available on satisfactory terms. Intense competition from established and emerging companies, some with greater resources, could hinder market acceptance and sales of its tests. Operational disruptions due to damage to facilities, reliance on single-source suppliers like Phillips-Medisize, Illumina, and Hamilton Company, or cyberattacks could severely harm business continuity and reputation. Regulatory uncertainties, particularly regarding healthcare reform, pricing, coverage, and reimbursement, pose significant challenges, with potential reductions in Medicare reimbursement rates under PAMA and the evolving regulation of LDTs. The company is also exposed to substantial costs and liability from litigation, including ongoing patent infringement lawsuits against Geneoscopy , and risks under federal and state anti-fraud and abuse laws, such as the Federal False Claims Act, which previously resulted in a $32.5 million settlement payment in September 2023 related to Medicare billing regulations . International expansion introduces risks related to compliance with diverse regulatory frameworks, foreign currency fluctuations, and political instability.

Management Priorities

Management's message to shareholders conveys a tone of strategic growth and operational efficiency, despite the pending acquisition by Abbott Laboratories. They emphasize the company's commitment to delivering innovative cancer screening and diagnostic tests, highlighting the achievement of over 5.5 million patient results in 2025 and an 18% revenue growth while decreasing operating expenses as a percentage of revenue . A key strategic priority is the continued investment in the product pipeline, evidenced by the launch of Cologuard Plus, Oncodetect, and Cancerguard tests, and the securing of Medicare reimbursement for Oncodetect . Another priority is driving operational leverage and efficiency through the multi-year productivity plan, which aims to deliver over $150 million in expected annual savings by 2026 . Finally, management is focused on the successful completion of the Merger with Abbott Laboratories, which is expected to occur in the second quarter of 2026, where each share of common stock will be converted into the right to receive $105.00 in cash .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Critical Accounting Policies and Estimates — Revenue Recognition
  3. [3] Item 1, Business — Our Screening Tests — Cologuard and Cologuard Plus Tests
  4. [4] Item 1, Business — Our Screening Tests — Cologuard and Cologuard Plus Tests
  5. [5] Item 1, Business — Our Screening Tests — Cologuard and Cologuard Plus Tests
  6. [6] Item 1, Business — Our Screening Tests — Cancerguard Test
  7. [7] Item 1, Business — Our Screening Tests — Genetic Testing
  8. [8] Item 1, Business — Our Precision Oncology Tests — Oncotype DX Breast Recurrence Score Test
  9. [9] Item 1, Business — Our Precision Oncology Tests — Oncotype DX Breast DCIS Score Test
  10. [10] Item 1, Business — Our Precision Oncology Tests — Oncotype DX Colon Recurrence Score Test
  11. [11] Item 1, Business — Our Precision Oncology Tests — Oncodetect Test
  12. [12] Item 1, Business — Our Precision Oncology Tests — OncoExTra Test
  13. [13] Item 1, Business — Our Precision Oncology Tests — Riskguard Test
  14. [14] Item 8, Consolidated Statements of Operations
  15. [15] Item 1, Business — Overview
  16. [16] Item 8, Consolidated Statements of Operations
  17. [17] Item 7, MD&A — Cost of sales
  18. [18] Item 8, Consolidated Statements of Operations
  19. [19] Item 8, Consolidated Statements of Operations
  20. [20] Item 8, Consolidated Statements of Operations
  21. [21] Item 8, Consolidated Statements of Operations
  22. [22] Item 8, Consolidated Statements of Cash Flows
  23. [23] Item 8, Consolidated Balance Sheets
  24. [24] Item 8, Consolidated Balance Sheets
  25. [25] Item 1A, Risk Factors — Risks Relating to our Securities
  26. [26] Item 7, MD&A — Results of Operations — Revenue
  27. [27] Item 7, MD&A — Results of Operations — Revenue
  28. [28] Item 7, MD&A — Results of Operations — Revenue
  29. [29] Item 7, MD&A — Results of Operations — Cost of sales
  30. [30] Item 7, MD&A — Results of Operations — Research and development expenses
  31. [31] Item 7, MD&A — Results of Operations — Sales and marketing expenses
  32. [32] Item 7, MD&A — Results of Operations — General and administrative expenses
  33. [33] Item 1, Business — Overview
  34. [34] Item 1, Business — Overview
  35. [35] Item 1, Business — Overview
  36. [36] Item 1, Business — Overview
  37. [37] Item 7, MD&A — Recent Developments and Trends — Multi-year Productivity Plan
  38. [38] Item 1, Business — Merger Agreement
  39. [39] Item 7, MD&A — Results of Operations — Revenue
  40. [40] Item 7, MD&A — Liquidity and Capital Resources — Overview
  41. [41] Item 7, MD&A — Product Opportunities
  42. [42] Item 7, MD&A — Product Opportunities
  43. [43] Item 7, MD&A — Product Opportunities
  44. [44] Item 1, Business — Pipeline Research and Development — Colorectal Cancer Screening Test Development
  45. [45] Item 11, Notes to Consolidated Financial Statements — (11) LICENSE AND COLLABORATION AGREEMENTS — Freenome Holdings, Inc.
  46. [46] Item 1, Business — Our Screening Tests — Cancerguard Test
  47. [47] Item 1, Business — Pipeline Research and Development — MCED Test Development
  48. [48] Item 1, Business — Pipeline Research and Development — MCED Test Development
  49. [49] Item 1, Business — Our Precision Oncology Tests — Oncodetect Test
  50. [50] Item 1, Business — Pipeline Research and Development — MRD Test Development
  51. [51] Item 7, MD&A — Results of Operations — Cost of sales
  52. [52] Item 7, MD&A — Results of Operations — Sales and marketing expenses
  53. [53] Item 7, MD&A — Results of Operations — General and administrative expenses
  54. [54] Item 7, MD&A — Recent Developments and Trends — Multi-year Productivity Plan
  55. [55] Item 1, Business — Pipeline Research and Development
  56. [56] Item 7, MD&A — Material Cash Requirements — Capital Expenditures
  57. [57] Item 1A, Risk Factors — Risks Relating to our Securities
  58. [58] Item 7, MD&A — Material Cash Requirements — Sources of Cash
  59. [59] Item 1A, Risk Factors — Risks Related to our Business and Business Strategy — Our success depends heavily on our Screening and Precision Oncology tests and the successful commercialization of our tests in development.
  60. [60] Item 1A, Risk Factors — Risks Relating to Product Development, Commercialization and Sales of our Products — If we do not successfully manage the launch and marketing of new products or services, our financial results could be adversely affected.
  61. [61] Item 1A, Risk Factors — Risks Relating to Product Development, Commercialization and Sales of our Products — The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate.
  62. [62] Item 1A, Risk Factors — Risks Related to our Business and Business Strategy — International expansion of our business exposes us to business, regulatory, labor, political, operational, financial, liability, compliance, payment collection, and economic risks associated with doing business outside of the U.S.
  63. [63] Item 1, Business — Regulation — International
  64. [64] Item 1A, Risk Factors — Risks Related to our Business and Business Strategy — Our business may be adversely affected by global macroeconomic conditions and volatility in the capital markets.
  65. [65] Item 1A, Risk Factors — Risks Relating to Governmental Regulation and Reimbursement — There exists substantial uncertainty regarding the future regulation of the LDTs.
  66. [66] Item 1, Business — Merger Agreement
  67. [67] Item 8, Consolidated Statements of Operations
  68. [68] Item 1A, Risk Factors — Risks Relating to our Intellectual Property — If we are unable to protect or enforce our intellectual property effectively, we may be unable to prevent third parties from using our intellectual property, which would impair any competitive advantage we may otherwise have.
  69. [69] Item 1A, Risk Factors — Risks Relating to Governmental Regulation and Reimbursement — Some of our activities may subject us to risks under federal, state, and foreign laws prohibiting “kickbacks” and false or fraudulent claims.
  70. [70] Item 1, Business — Overview
  71. [71] Item 1, Business — Overview
  72. [72] Item 1, Business — Overview
  73. [73] Item 7, MD&A — Recent Developments and Trends — Multi-year Productivity Plan
  74. [74] Item 1, Business — Merger Agreement

Analysis on 5/21/2026